- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 764395, 17 pages
Altered Sympathetic-to-Immune Cell Signaling via β2-Adrenergic Receptors in Adjuvant Arthritis
1Hoover Arthritis Research Center, Banner Health Research Institute, 10515 W. Santa Fe Drive, Sun City, AZ 85351, USA
2Department of Psychology, Kent State University, 133 Kent Hall, Kent, OH 44242, USA
3Kent-Summa Institute for Clinical and Translational Research, Summa Health System, 525 East Market Street, Akron,OH 44304, USA
4Department of Pathology and Human Anatomy, Alumni Hall for Basic Sciences, Loma Linda University School of Medicine, 11021 Campus Street, Loma Linda, CA 92354, USA
Received 4 May 2013; Accepted 2 August 2013
Academic Editor: Jianying Zhang
Copyright © 2013 Dianne Lorton et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- C. G. O. Baerwald, G. R. Burmester, and A. Krause, “Interactions of autonomic nervous, neuroendocrine, and immune systems in rheumatoid arthritis,” Rheumatic Disease Clinics of North America, vol. 26, no. 4, pp. 841–857, 2000.
- D. Lorton, C. Lubahn, and D. L. Bellinger, “Potential use of drugs that target neural-immune pathways in the treatment of rheumatoid arthritis and other autoimmune diseases,” Current Drug Targets. Inflammation and Allergy, vol. 2, no. 1, pp. 1–30, 2003.
- F. A. Koopman, S. P. Stoof, R. H. Straub, M. A. Van Maanen, M. J. Vervoordeldonk, and P. P. Tak, “Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis,” Molecular Medicine, vol. 17, no. 9-10, pp. 937–948, 2011.
- J. D. Levine, S. J. Dardick, and M. F. Roizen, “Contribution of sensory afferents and sympathetic efferents to joint injury in experimental arthritis,” Journal of Neuroscience, vol. 6, no. 12, pp. 3423–3429, 1986.
- C. L. Lubahn, J. A. Schaller, D. L. Bellinger, S. Sweeney, and D. Lorton, “The importance of timing of adrenergic drug delivery in relation to the induction and onset of adjuvant-induced arthritis,” Brain, Behavior, and Immunity, vol. 18, no. 6, pp. 563–571, 2004.
- A.-M. Malfait, A. S. Malik, L. Marinova-Mutafchieva, D. M. Butler, R. N. Maini, and M. Feldmann, “The β2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: mechanisms of action,” Journal of Immunology, vol. 162, no. 10, pp. 6278–6283, 1999.
- P. Härle, D. Möbius, D. J. J. Carr, J. Schölmerich, and R. H. Straub, “An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1305–1313, 2005.
- C. G. O. Baerwald, M. Laufenberg, T. Specht, P. Von Wichert, G. R. Burmester, and A. Krause, “Impaired sympathetic influence on the immune response in patients with rheumatoid arthritis due to lymphocyte subset-specific modulation of β2-adrenergic receptors,” British Journal of Rheumatology, vol. 36, no. 12, pp. 1262–1269, 1997.
- C. G. O. Baerwald, M. Wahle, T. Ulrichs et al., “Reduced catecholamine response of lymphocytes from patients with rheumatoid arthritis,” Immunobiology, vol. 200, no. 1, pp. 77–91, 1999.
- M. Wahle, A. Krause, T. Ulrichs et al., “Disease activity related catecholamine response of lymphocytes from patients with rheumatoid arthritis,” Annals of the New York Academy of Sciences, vol. 876, pp. 287–297, 1999.
- M. Wahle, A. Krause, S. Kölker, P. Von Wichert, and C. G. O. Baerwald, “Intracellular cAMP and β2-adrenergic receptors on CD19+ lymphocytes in patients with rheumatoid arthritis,” Annals of the New York Academy of Sciences, vol. 876, pp. 309–311, 1999.
- M. Wahle, S. Kölker, A. Krause, G. R. Burmester, and C. G. O. Baerwald, “Impaired catecholaminergic signalling of B lymphocytes in patients with chronic rheumatic diseases,” Annals of the Rheumatic Diseases, vol. 60, no. 5, pp. 505–510, 2001.
- M. S. Lombardi, A. Kavelaars, M. Schedlowski et al., “Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis,” The FASEB Journal, vol. 13, no. 6, pp. 715–725, 1999.
- M. S. Lombardi, A. Kavelaars, P. M. Cobelens, R. E. Schmidt, M. Schedlowski, and C. J. Heijnen, “Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system,” Journal of Immunology, vol. 166, no. 3, pp. 1635–1640, 2001.
- R. J. Lefkowitz and S. K. Shenoy, “Transduction of receptor signals by β-arrestins,” Science, vol. 308, no. 5721, pp. 512–517, 2005.
- R. B. Clark, B. J. Knoll, and R. Barber, “Partial agonists and G protein-coupled receptor desensitization,” Trends in Pharmacological Sciences, vol. 20, no. 7, pp. 279–286, 1999.
- H. A. Rockman, W. J. Koch, and R. J. Lefkowitz, “Seven-transmembrane-spanning receptors and heart function,” Nature, vol. 415, no. 6868, pp. 206–212, 2002.
- T. M. Tran, J. Friedman, E. Qunaibi, F. Baameur, R. H. Moore, and R. B. Clark, “Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies,” Molecular Pharmacology, vol. 65, no. 1, pp. 196–206, 2004.
- W. P. Hausdorff, M. Bouvier, B. F. O'Dowd, G. P. Irons, M. G. Caron, and R. J. Lefkowitz, “Phosphorylation sites on two domains of the β2-adrenergic receptor are involved in distinct pathways of receptor desensitization,” Journal of Biological Chemistry, vol. 264, no. 21, pp. 12657–12665, 1989.
- M. J. Lohse, J. L. Benovic, J. Codina, M. G. Cargon, and R. J. Lefkowitz, “β-Arrestin: a protein that regulates β-adrenergic receptor function,” Science, vol. 248, no. 4962, pp. 1547–1550, 1990.
- R. J. Lefkowitz, “G protein-coupled receptors: III. New roles for receptor kinases and β- arrestins in receptor signaling and desensitization,” Journal of Biological Chemistry, vol. 273, no. 30, pp. 18677–18680, 1998.
- N. J. Freedman and R. J. Lefkowitz, “Desensitization of G protein-coupled receptors,” Recent Progress in Hormone Research, vol. 51, pp. 319–351, 1996.
- J. G. Krupnick and J. L. Benovic, “The role of receptor kinases and arrestins in G protein-coupled receptor regulation,” Annual Review of Pharmacology and Toxicology, vol. 38, pp. 289–319, 1998.
- J. Goodman O.B. Jr., J. G. Krupnick, F. Santini et al., “β-Arrestin acts as a clathrin adaptor in endocytosis of the β2- adrenergic receptor,” Nature, vol. 383, no. 6599, pp. 447–450, 1996.
- S. A. Laporte, R. H. Oakley, J. Zhang et al., “The β2-adrenergic receptor/βarrestin complex recruits the clathrin adaptor AP-2 during endocytosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3712–3717, 1999.
- S. S. G. Ferguson, W. E. Downey III, A.-M. Colapietro, L. S. Barak, L. Ménard, and M. G. Caron, “Role of β-arrestin in mediating agonist-promoted G protein-coupled receptor internalization,” Science, vol. 271, no. 5247, pp. 363–366, 1996.
- S. K. Shenoy, M. T. Drake, C. D. Nelson et al., “β-arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor,” Journal of Biological Chemistry, vol. 281, no. 2, pp. 1261–1273, 2006.
- M. Trester-Zedlitz, A. Burlingame, B. Kobilka, and M. Von Zastrow, “Mass spectrometric analysis of agonist effects on posttranslational modifications of the β-2 adrenoceptor in mammalian cells,” Biochemistry, vol. 44, no. 16, pp. 6133–6143, 2005.
- E. E. Millman, J. L. Rosenfeld, D. J. Vaughan et al., “Endosome sorting of β2-adrenoceptors is GRK5 independent,” British Journal of Pharmacology, vol. 141, no. 2, pp. 277–284, 2004.
- L. M. Luttrell, F. L. Roudabush, E. W. Choy et al., “Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2449–2454, 2001.
- P. H. McDonald, C.-W. Chow, W. E. Miller et al., “β-Arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3,” Science, vol. 290, no. 5496, pp. 1574–1577, 2000.
- L. M. Luttrell, S. S. G. Ferguson, Y. Daaka et al., “β-arrestin-dependent formation of β2 adrenergic receptor-src protein kinase complexes,” Science, vol. 283, no. 5402, pp. 655–661, 1999.
- Y. Sun, Z. Cheng, L. Ma, and G. Pei, “β-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation,” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49212–49219, 2002.
- K.-S. Kim, D. H. Park, T. C. Wessel, B. Song, J. A. Wagner, and T. H. Joh, “A dual role for the cAMP-dependent protein kinase in tyrosine hydroxylase gene expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 8, pp. 3471–3475, 1993.
- J. Pitcher, M. J. Lohse, J. Codina, M. G. Caron, and R. J. Lefkowitz, “Desensitization of the isolated β2-adrenergic receptor by β-adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms,” Biochemistry, vol. 31, no. 12, pp. 3193–3197, 1992.
- W. Kuis, C. C. E. Van Steenwijk, G. Sinnema et al., “The autonomic nervous system and the immune system in juvenile rheumatoid arthritis,” Brain, Behavior, and Immunity, vol. 10, no. 4, pp. 387–398, 1996.
- I. Leden, A. Eriksson, and B. Lilja, “Autonomic nerve function in rheumatoid arthritis of varying severity,” Scandinavian Journal of Rheumatology, vol. 12, no. 2, pp. 166–170, 1983.
- F. Perry, P. H. Heller, J. Kamiya, and J. D. Levine, “Altered autonomic function in patients with arthritis or with chronic myofascial pain,” Pain, vol. 39, no. 1, pp. 77–84, 1989.
- L. Stojanovich, “Autonomic dysfunction in autoimmune rheumatic disease,” Autoimmunity Reviews, vol. 8, no. 7, pp. 569–572, 2009.
- D. Lorton, C. Lubahn, S. Y. Felten, and D. L. Bellinger, “Norepinephrine content in primary and secondary lymphoid organs is altered in rats with adjuvant-induced arthritis,” Mechanisms of Ageing and Development, vol. 94, pp. 145–163, 1997, Erratum in, Mechanisms of Ageing and Development, vol. 98, pp. 181–183, 1997.
- D. Lorton, D. L. Bellinger, T. Osredkar, J. Schaller, and C. Lubahn, “Sympathetic signaling splenocytes is altered in adjuvant induced arthritis (AA),” Brain Behavior and Immunity, vol. 25, p. S209, 2011.
- D. Lorton, C. Lubahn, N. Klein, J. Schaller, and D. L. Bellinger, “Dual role for noradrenergic innervation of lymphoid tissue and arthritic joints in adjuvant-induced arthritis,” Brain, Behavior, and Immunity, vol. 13, no. 4, pp. 315–334, 1999.
- M. Wahle, G. Hanefeld, S. Brunn et al., “Failure of catecholamines to shift T-cell cytokine responses toward a Th2 profile in patients with rheumatoid arthritis,” Arthritis Research and Therapy, vol. 8, no. 5, article R138, 2006.
- O. Malysheva, M. Pierer, U. Wagner, M. Wahle, U. Wagner, and C. G. Baerwald, “Association between β2 adrenergic receptor polymorphisms and rheumatoid arthritis in conjunction with human leukocyte antigen (HLA)-DRB1 shared epitope,” Annals of the Rheumatic Diseases, vol. 67, no. 12, pp. 1759–1764, 2008.
- A. Ahles, F. Rochais, T. Frambach, M. Bünemann, and S. Engelhardt, “A polymorphism-specific “memory” mechanism in the β2-adrenergic receptor,” Science Signaling, vol. 4, no. 185, article ra53, 2011.
- K. M. Small, D. W. McGraw, and S. B. Liggett, “Pharmacology and physiology of human adrenergic receptor polymorphisms,” Annual Review of Pharmacology and Toxicology, vol. 43, pp. 381–411, 2003.
- P. A. Insel, “β2-adrenergic receptor polymorphisms and signaling: Do variants influence the “memory” of receptor activation?” Science Signaling, vol. 4, no. 185, article pe37, 2011.
- D. Lorton, C. Lubahn, C. A. Lindquist, J. Schaller, C. Washington, and D. L. Bellinger, “Changes in the density and distribution of sympathetic nerves in spleens from Lewis rats with adjuvant-induced arthritis suggest that an injury and sprouting response occurs,” Journal of Comparative Neurology, vol. 489, no. 2, pp. 260–273, 2005.
- H. Tanaka, Y. Ueta, U. Yamashita, H. Kannan, and H. Yamashita, “Biphasic changes in behavioral, endocrine, and sympathetic systems in adjuvant arthritis in Lewis rats,” Brain Research Bulletin, vol. 39, no. 1, pp. 33–37, 1996.
- A. A. Teixeira, I. Azevedo, D. Branco, E. Rodrigues-Pereira, and W. Osswald, “Sympathetic denervation caused by long-term noradrenaline infusions; prevention by desipramine and superoxide dismutase,” British Journal of Pharmacology, vol. 97, no. 1, pp. 95–102, 1989.
- A. Terao, M. Oikawa, and M. Saito, “Tissue-specific increase in norepinephrine turnover by central interleukin-1, but not by interleukin-6, in rats,” American Journal of Physiology. Regulatory Integrative and Comparative Physiology, vol. 266, no. 2, pp. R400–R404, 1994.
- J. C. Meltzer, B. J. MacNeil, V. Sanders et al., “Stress-induced suppression of in vivo splenic cytokine production in the rat by neural and hormonal mechanisms,” Brain, Behavior, and Immunity, vol. 18, no. 3, pp. 262–273, 2004.
- B. G. Helwig, R. A. Craig, R. J. Fels, F. Blecha, and M. J. Kenney, “Central nervous system administration of interleukin-6 produces splenic sympathoexcitation,” Autonomic Neuroscience, vol. 141, no. 1-2, pp. 104–111, 2008.
- J. Fan and A. B. Malik, “Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors,” Nature Medicine, vol. 9, pp. 315–321, 2003.
- K. Loniewski, Y. Shi, J. Pestka, and N. Parameswaran, “Toll-like receptors differentially regulate GPCR kinases and arrestins in primary macrophages,” Molecular Immunology, vol. 45, no. 8, pp. 2312–2322, 2008.
- A. Krause, A. Steitz, P. Von Wichert, and C. Baerwald, “Influence of cytokines on the density of β2-adrenergic receptors on peripheral blood mononuclear cells in vitro,” Cytokine, vol. 7, no. 3, pp. 273–276, 1995.
- I. L. Korichneva and V. A. Tkachuk, “Alterations in beta-adrenoceptor density on T-lymphocytes upon activation with interleukin-2 and phytohaemagglutinin,” Biomedical Science, vol. 1, no. 1, pp. 84–88, 1990.
- T. Nakane, T. Szentendrei, L. Stern, M. Virmani, J. Seely, and G. Kunos, “Effects of IL-1 and cortisol on β-adrenergic receptors, cell proliferation, and differentiation in cultured human A549 lung tumor cells,” Journal of Immunology, vol. 145, no. 1, pp. 260–266, 1990.
- P. Larsson, R. Holmdahl, L. Dencker, and L. Klareskog, “In vivo treatment with W3/13 (anti-pan T) but not with OX8 (anti-suppressor/cytotoxic T) monoclonal antibodies impedes the development of adjuvant arthritis in rats,” Immunology, vol. 56, no. 3, pp. 383–391, 1985.
- C. Pelegrí, M. P. Morante, C. Castellote, M. Castell, and A. Franch, “Administration of a nondepleting anti-CD4 monoclonal antibody (W3/25) prevents adjuvant arthritis, even upon rechallenge: parallel administration of a depleting anti-CD8 monoclonal antibody (OX8) does not modify the effect of W3/25,” Cellular Immunology, vol. 165, no. 2, pp. 177–182, 1995.
- C. Pelegrí, M. P. Morante, C. Castellote, A. Franch, and M. Castell, “Treatment with an anti-CD4 monoclonal antibody strongly ameliorates established rat adjuvant arthritis,” Clinical and Experimental Immunology, vol. 103, no. 2, pp. 273–278, 1996.
- M. A. Swanson, W. T. Lee, and V. M. Sanders, “IFN-γ production by Th1 cells generated from naive CD4+ T cells exposed to norepinephrine,” Journal of Immunology, vol. 166, no. 1, pp. 232–240, 2001.
- R. H. Straub, L. Rauch, A. Fassold, T. Lowin, and G. Pongratz, “Neuronally released sympathetic neurotransmitters stimulate splenic interferon-γ secretion from T cells in early type II collagen-induced arthritis,” Arthritis and Rheumatism, vol. 58, no. 11, pp. 3450–3460, 2008.
- M. G. Guereschi, L. P. Araujo, J. T. Maricato et al., “Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner,” European Journal of Immunology, vol. 43, no. 4, pp. 1001–1012, 2013.
- J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336, 2003.
- S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003.
- M. E. Brunkow, E. W. Jeffery, K. A. Hjerrild et al., “Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse,” Nature Genetics, vol. 27, no. 1, pp. 68–73, 2001.
- J. J. Lafaille, K. Nagashima, M. Katsuki, and S. Tonegawa, “High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice,” Cell, vol. 78, no. 3, pp. 399–408, 1994.
- F. Van De Keere and S. Tonegawa, “CD4+ T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice,” Journal of Experimental Medicine, vol. 188, no. 10, pp. 1875–1882, 1998.
- T. A. Chatila, F. Blaeser, N. Ho et al., “JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome,” Journal of Clinical Investigation, vol. 106, no. 12, pp. R75–R81, 2000.
- S. Bhowmick, A. Singh, R. A. Flavell, R. B. Clark, J. O'Rourke, and R. E. Cone, “The sympathetic nervous system modulates CD4+FoxP3+ regulatory T cells via a TGF-β-dependent mechanism,” Journal of Leukocyte Biology, vol. 86, no. 6, pp. 1275–1283, 2009.